Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 26, 2016 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the...
June 21, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific’s Dynabeads™ CD3/CD28 Cell Therapy System

PHILADELPHIA and OXFORD, United Kingdom, June 21, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered...
June 20, 2016 09:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European...
June 16, 2016 11:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at the 2016 JMP Life Sciences Conference

PHILADELPHIA and OXFORD, United Kingdom, June 16, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian...
June 05, 2016 09:05 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting

PHILADELPHIA and OXFORD, United Kingdom, June 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster...
June 02, 2016 11:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at the Jefferies 2016 Healthcare Conference

PHILADELPHIA and OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble,...
May 24, 2016 07:32 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Succession Plan for Chairman at End of 2016

PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer,...
May 24, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Strengthens Board with Appointment of Barbara Duncan

PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer,...
May 19, 2016 09:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at the 2016 UBS Global Healthcare Conference

PHILADELPHIA and OXFORD, United Kingdom, May 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble,...
May 12, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports First Quarter 2016 Financial Results

PHILADELPHIA and OXFORD, United Kingdom, May 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer,...